• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Molecules . Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2

tetano

Editor, Senior Moderator
Molecules


. 2022 Feb 4;27(3):1052.
doi: 10.3390/molecules27031052.
Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication


Dorothée Bardiot[SUP] 1 [/SUP], Laura Vangeel[SUP] 2 [/SUP], Mohamed Koukni[SUP] 1 [/SUP], Philippe Arzel[SUP] 1 [/SUP], Marleen Zwaagstra[SUP] 3 [/SUP], Heyrhyoung Lyoo[SUP] 3 [/SUP], Patrick Wanningen[SUP] 4 [/SUP], Shamshad Ahmad[SUP] 5 [/SUP], Linlin Zhang[SUP] 6 [/SUP], Xinyuanyuan Sun[SUP] 6 [/SUP], Adrien Delpal[SUP] 7 [/SUP], Cecilia Eydoux[SUP] 7 [/SUP], Jean-Claude Guillemot[SUP] 7 [/SUP], Eveline Lescrinier[SUP] 8 [/SUP], Hugo Klaassen[SUP] 1 [/SUP], Pieter Leyssen[SUP] 2 [/SUP], Dirk Jochmans[SUP] 2 [/SUP], Karolien Castermans[SUP] 1 [/SUP], Rolf Hilgenfeld[SUP] 6 9 [/SUP], Colin Robinson[SUP] 5 [/SUP], Etienne Decroly[SUP] 7 [/SUP], Bruno Canard[SUP] 7 [/SUP], Eric J Snijder[SUP] 4 [/SUP], Martijn J van Hemert[SUP] 4 [/SUP], Frank van Kuppeveld[SUP] 3 [/SUP], Patrick Chaltin[SUP] 1 10 [/SUP], Johan Neyts[SUP] 2 [/SUP], Steven De Jonghe[SUP] 2 [/SUP], Arnaud Marchand[SUP] 1 [/SUP]



Affiliations

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has led to a pandemic, that continues to be a huge public health burden. Despite the availability of vaccines, there is still a need for small-molecule antiviral drugs. In an effort to identify novel and drug-like hit matter that can be used for subsequent hit-to-lead optimization campaigns, we conducted a high-throughput screening of a 160 K compound library against SARS-CoV-2, yielding a 1-heteroaryl-2-alkoxyphenyl analog as a promising hit. Antiviral profiling revealed this compound was active against various beta-coronaviruses and preliminary mode-of-action experiments demonstrated that it interfered with viral entry. A systematic structure-activity relationship (SAR) study demonstrated that a 3- or 4-pyridyl moiety on the oxadiazole moiety is optimal, whereas the oxadiazole can be replaced by various other heteroaromatic cycles. In addition, the alkoxy group tolerates some structural diversity.

Keywords: 1,2,4-oxadiazole; 1-heteroaryl-2-alkoxyphenyl analogs; COVID-19; SARS-CoV-2.
 
Back
Top Bottom